Sygnature Discovery has acquired of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes in vivo services for biotechs, pharmaceutical companies and academics. Until the acquisition, Alderley Oncology was run by Bruntwood SciTech, owners of Alderley Park. The value of the deal has not been disclosed.
The Cheshire-based team offers a variety of in vivo services for cancer drug discovery. These assessments will help define the path to the clinic and identify the anticipated patient populations who might best respond to treatment.
Alderley Oncology was established by Jane Kendrew in 2017. Kendrew and the team have experience in the field, much of it gained at AstraZeneca.
“We are delighted to be joining Sygnature Discovery,” Kendrew said. “We look forward to working with them as part of the wider team serving the oncology drug discovery community, and patients living with cancer.”
"We are pleased to welcome Jane and her colleagues to Sygnature Discovery," said Dr. Stuart Onions, Director of Research Management at Sygnature. "The team’s expertise in oncology and immuno-oncology in vivo models will significantly enhance our integrated oncology provision, delivering further value to our integrated projects for clients and, importantly, allow us to more efficiently and effectively deliver potential new therapeutics into pre-clinic development."
The deal complements the 2018 acquisition of Nottingham-based RenaSci, which added complementary in vivo expertise in abuse and dependence, metabolic diseases, CNS disorders, and liver and kidney disease to Sygnature’s in vitro services. The company is now able to offer its clients a full suite of in vitro and in vivo laboratory assays and considerable intellectual input in cancer drug discovery, too. It also expands Sygnature’s existing footprint at Alderley Park, where it currently has part of its DMPK department.
"The acquisition of Alderley Oncology expands and enhances our drug discovery services portfolio, and further boosts our on-going investments in oncology," Sygnature CEO Dr Simon said. "We have already delivered five oncology pre-clinical candidates for clients. Sygnature has an expanding portfolio of integrated programmes in oncology and immuno-oncology with clients in the USA and Europe. The added expertise gained from Alderley Oncology will greatly assist in advancing these projects into pre-clinical development."